Dynamics of HLA and angiotensin II type 1 receptor antibodies during pregnancy.

Alloimmunization Angiotensin II type 1 receptor Antibodies Human leukocyte antigen Pregnancy

Journal

Human immunology
ISSN: 1879-1166
Titre abrégé: Hum Immunol
Pays: United States
ID NLM: 8010936

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 12 06 2023
revised: 23 11 2023
accepted: 03 01 2024
pubmed: 19 1 2024
medline: 19 1 2024
entrez: 18 1 2024
Statut: ppublish

Résumé

Alloantibodies, especially anti-human leukocyte antigen antibodies (HLA antibodies), and autoantibodies, as angiotensin II type 1 receptor antibodies (AT1R antibodies), may complicate the access and the course of transplantation. Pregnancy is a known source of HLA antibodies, with most studies evaluating pregnancy-induced sensitization by complement-dependent cytotoxicity assays, mainly after childbirth. AT1R antibodies have been evaluated in the context of preeclampsia. We aimed to evaluate pregnancy as a natural source of HLA antibodies and AT1R antibodies, their dynamics along gestation and the potential factors involved in antibody appearance. Serum samples from pregnant women were collected during the three trimesters of pregnancy (1T, 2T, 3T). Presence of HLA antibodies was assessed by screening beads on Luminex and AT1R antibodies by ELISA. A cohort of 138 pregnant women were included. Samples from all were tested in 1T, 127 in 2T and 102 in 3T. HLA antibodies increased from 29.7 % (1T) to 38.2 % (3T). AT Pregnancy is a relevant source of HLA antibodies sensitization, but not of AT

Sections du résumé

BACKGROUND BACKGROUND
Alloantibodies, especially anti-human leukocyte antigen antibodies (HLA antibodies), and autoantibodies, as angiotensin II type 1 receptor antibodies (AT1R antibodies), may complicate the access and the course of transplantation. Pregnancy is a known source of HLA antibodies, with most studies evaluating pregnancy-induced sensitization by complement-dependent cytotoxicity assays, mainly after childbirth. AT1R antibodies have been evaluated in the context of preeclampsia. We aimed to evaluate pregnancy as a natural source of HLA antibodies and AT1R antibodies, their dynamics along gestation and the potential factors involved in antibody appearance.
METHODS METHODS
Serum samples from pregnant women were collected during the three trimesters of pregnancy (1T, 2T, 3T). Presence of HLA antibodies was assessed by screening beads on Luminex and AT1R antibodies by ELISA.
RESULTS RESULTS
A cohort of 138 pregnant women were included. Samples from all were tested in 1T, 127 in 2T and 102 in 3T. HLA antibodies increased from 29.7 % (1T) to 38.2 % (3T). AT
CONCLUSIONS CONCLUSIONS
Pregnancy is a relevant source of HLA antibodies sensitization, but not of AT

Identifiants

pubmed: 38238229
pii: S0198-8859(24)00001-6
doi: 10.1016/j.humimm.2024.110749
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110749

Informations de copyright

Copyright © 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Carla Burballa (C)

Department of Nephrology, Hospital del Mar, Barcelona, Spain; Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Laura Llinàs-Mallol (L)

Department of Nephrology, Hospital del Mar, Barcelona, Spain; Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Susana Vázquez (S)

Department of Nephrology, Hospital del Mar, Barcelona, Spain; Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

M José Pérez-Sáez (MJ)

Department of Nephrology, Hospital del Mar, Barcelona, Spain; Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Carlos Arias-Cabrales (C)

Department of Nephrology, Hospital del Mar, Barcelona, Spain; Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Anna Buxeda (A)

Department of Nephrology, Hospital del Mar, Barcelona, Spain; Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

José Luís Hernandez (JL)

Department of Obstetrics and Gynecology, Hospital del Mar, Barcelona, Spain.

Marta Riera (M)

Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Sara Sanz (S)

Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Elisenda Alari-Pahissa (E)

Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Judith Federico-Vega (J)

Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Jorge Eguía (J)

Laboratori de Referència de Catalunya SA, Barcelona, Spain.

Julio Pascual (J)

Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain.

Dolores Redondo-Pachón (D)

Department of Nephrology, Hospital del Mar, Barcelona, Spain; Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Marta Crespo (M)

Department of Nephrology, Hospital del Mar, Barcelona, Spain; Nephropathies Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. Electronic address: mcrespo@psmar.cat.

Classifications MeSH